106429-38-3

Basic information

• Product Name: 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI)
• Synonyms: 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI);1H-Benzimidazole-6-carboxylicacid, 2-amino-, methyl ester
• CAS NO: 106429-38-3
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.19
• Product Categories: AMINOACID;BENZIMIDAZOLE;pharmacetical
• Mol File: 106429-38-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 427°Cat760mmHg
• Flash Point: 212.1°C
• Appearance: /
• Density: 1.413g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.766
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.56±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI)(106429-38-3)
• EPA Substance Registry System: 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI)(106429-38-3)

Safety Data

• Hazardous Substances Data: 106429-38-3(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole-5-carboxylic acid, 2-amino-, methyl ester (9CI) is a chemical compound with the molecular formula C9H9N3O2. It is a methyl ester derivative of 1H-benzimidazole-5-carboxylic acid, containing an amino group at the second carbon. 1H-Benzimidazole-5-carboxylicacid,2-amino-,methylester(9CI) is a potential intermediate in the synthesis of various pharmaceuticals and organic compounds. It has potential applications in the pharmaceutical industry due to its structural properties and reactivity. However, further research is needed to fully understand its potential uses and properties.

InChI:InChI=1/C8H5BrN2O2/c9-4-1-2-5-6(3-4)11-7(10-5)8(12)13/h1-3H,(H,10,11)(H,12,13)

Upstream product

• 506-68-3 bromocyane 
• 36692-49-6 Methyl 3,4-diaminobenzoate 

Downstream Products

• 1446200-43-6 methyl 2-(2-(2-(trifluoromethoxy)benzamido)-thiazole-4-carboxamido)-1H-benzo[d]imidazole-5-carboxylate 

Relevant articles and documents

Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives

Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of Pseudomonas and more particularly P. aeruginosa.

The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii

Multidrug-resistant bacterial infections continue to be a rising global health concern. Herein is described the development of a class of novel 2-aminobenzimidazoles with antibiotic activity. These active 2-aminobenzimidazoles retain their antibiotic activity against several strains of multidrug-resistant Staphylococcus aureus and Acinetobacter baumannii when compared to susceptible strains.

Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library

An inhibitor of the complex of factor VIIa and tissue factor (fVIIa/TF), 2-substituted-4-amidinophenylpyruvic acid 1a, was structurally modified with the aim of increasing its potency and selectivity. The lead compound 1a was originally found in our factor Xa (fXa) inhibitor library on the basis of structural similarity of the primary binding sites of fVIIa and fXa. The design was based on computational docking studies using the extracted active site of fVIIa. Compound 1j was found to inhibit factor VIIa/TF at nanomolar concentration with improved selectivity versus fXa and thrombin and it preferentially prolonged the clotting time in the TF-dependent extrinsic pathway.